{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:45:01Z","timestamp":1777934701525,"version":"3.51.4"},"reference-count":38,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Drug-related problems (DRPs) represent a major challenge in contemporary oncology. In healthcare systems with limited clinical pharmacy resources, identification of high-risk patient groups and treatment settings is \u2013 from a clinical pharmacology perspective \u2013 essential to prioritize pharmacotherapeutic surveillance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-centre, retrospective, high-risk cohort study analysed pharmacotherapy in 31 adult cancer patients hospitalized in a comprehensive oncology centre in Poland. Patients were selected for medication review based on clinicians\u2019 suspicion of pharmacotherapy-related problems during hospitalization. DRPs were identified and classified according to the Pharmaceutical Care Network Europe classification version 9.1, focusing on pharmacotherapy-related complications rather than individual prescribing errors. Sociodemographic, clinical and pharmacotherapeutic variables were analysed. Statistical analyses were exploratory and hypothesis-generating.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At least one DRP was identified in 29 out of 31 patients (94%). The most frequent DRPs were adverse drug reactions and drug therapy without a clearly documented current indication, predominantly involving proton pump inhibitors (PPIs). Antimicrobials, drugs for acid-related disorders and psycholeptics accounted for the highest number of DRPs. A numerically higher risk of DRPs was observed in patients with impaired renal function, excessive polypharmacy (\u2265 10 drugs) and those receiving non-surgical treatment, particularly radiotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Hospitalized oncology patients with suspected pharmacotherapy-related complications are at high risk of DRPs. From an oncology pharmacy perspective, targeted medication review appears to be a rational approach to identify and mitigate pharmacotherapy-related risks in this setting. Radiotherapy units, patients with impaired renal function, antimicrobials and PPI use or extensive polypharmacy represent priority areas for enhanced clinical pharmacy involvement.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552261422639","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T05:46:41Z","timestamp":1772257601000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Drug-related problems in hospitalized oncology patients, with special focus on radiotherapy units: Implications for oncology pharmacy practice"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9584-3128","authenticated-orcid":false,"given":"Katarzyna","family":"Regulska","sequence":"first","affiliation":[{"name":"Greater Poland Cancer Centre"},{"name":"Research and Implementation Unit, Greater Poland Cancer Center, Garbary 15 Street, 61-866 Poznan, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcin","family":"Michalak","sequence":"additional","affiliation":[{"name":"Greater Poland Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beata","family":"Janiszewska","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Biopharmacy, Poznan University of Medical Sciences, Collegium Pharmaceuticum"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz","family":"Kolenda","sequence":"additional","affiliation":[{"name":"Research and Implementation Unit, Greater Poland Cancer Center, Garbary 15 Street, 61-866 Poznan, Poland"},{"name":"Department of Microbiology, Greater Poland Cancer Centre, Garbary 15 Street, 61-866 Poznan, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulina","family":"Gieremek","sequence":"additional","affiliation":[{"name":"Greater Poland Cancer Centre"},{"name":"Chair and Department of Pharmaceutical Chemistry, Poznan University of Medical Sciences, Grunwaldzka 6 Street, 60-780 Poznan, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konrad","family":"Lewandowski","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Biopharmacy, Poznan University of Medical Sciences, Collegium Pharmaceuticum"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beata","family":"Stanisz","sequence":"additional","affiliation":[{"name":"Chair and Department of Pharmaceutical Chemistry, Poznan University of Medical Sciences, Grunwaldzka 6 Street, 60-780 Poznan, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edyta","family":"Sza\u0142ek","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Biopharmacy, Poznan University of Medical Sciences, Collegium Pharmaceuticum"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34642"},{"key":"e_1_3_3_3_2","unstructured":"Pharmaceutical Care Network Europe Association. Classification for drug-related problems V9.1 [Internet]. 2022 [cited 2022 Nov 20]. Available from: https:\/\/www.pcne.org\/upload\/files\/417_PCNE_classification_V9-1_final.pdf."},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2020.531038"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.5604\/17322693.1092701"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.5603\/RPOR.a2023.0059"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/agm2.12051"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2014.03.008"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cger.2022.05.010"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2001.00892.x"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2010.11.014"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/glaa128"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjopharm.2010.03.005"},{"key":"e_1_3_3_14_2","first-page":"555","article-title":"Real-world direct health care costs associated with psychotropic polypharmacy among adults with common cancer types in the United States","volume":"25","author":"Vyas AM","year":"2019","unstructured":"Vyas AM, Kogut SJ, Aroke H. Real-world direct health care costs associated with psychotropic polypharmacy among adults with common cancer types in the United States. J Manag Care Spec Pharm 2019; 25: 555\u2013565.","journal-title":"J Manag Care Spec Pharm"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2022.02.007"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-148731"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2013.827660"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.120"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/107327489700400505"},{"key":"e_1_3_3_20_2","unstructured":"Polish summary of product characteristics database [Internet]. 2023 [cited 2023 Mar 31]. Available from: https:\/\/rejestry.ezdrowie.gov.pl\/rpl\/search\/public."},{"key":"e_1_3_3_21_2","unstructured":"National Antibiotic Program. Recommendations of the National Antibiotic Program [Internet]. 2023 [cited 2023 Mar 31]. Available from: https:\/\/antybiotyki.edu.pl\/rekomendacje\/rekomendacje-diagnostyki-i-terapii-zakazen\/."},{"key":"e_1_3_3_22_2","unstructured":"Woosley RL Heise CW Gallo T et al. QT drugs list [Internet]. 2023 [cited 2023 Mar 31]. Available from: https:\/\/crediblemeds.org."},{"key":"e_1_3_3_23_2","first-page":"11","article-title":"Pharmacotherapy of pain in cancer patients: recommendations of Polish scientific societies","volume":"18","author":"Wordliczek J","year":"2018","unstructured":"Wordliczek J, Kotli\u0144ska-Lemieszek A, Leppert W, et al. Pharmacotherapy of pain in cancer patients: recommendations of Polish scientific societies. B\u00f3l 2018; 18: 11\u201353.","journal-title":"B\u00f3l"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.18372"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-013-0118-4"},{"key":"e_1_3_3_26_2","first-page":"10","article-title":"Polish criteria for potentially incorrect pharmacotherapy in geriatrics","author":"Podczaska-Neumann A","year":"2019","unstructured":"Podczaska-Neumann A, Tobis K, Grze\u015bkowiak E. Polish criteria for potentially incorrect pharmacotherapy in geriatrics. Geriatria 2019: 10\u201315.","journal-title":"Geriatria"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjqs-2019-009552"},{"key":"e_1_3_3_28_2","first-page":"56","article-title":"Luka kadrowa","volume":"22","author":"Regulska K","year":"2023","unstructured":"Regulska K. Luka kadrowa. Farmacja Wielkopolska 2023; 22: 56\u201357.","journal-title":"Farmacja Wielkopolska"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-80560-2"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-021-01099-3"},{"key":"e_1_3_3_31_2","first-page":"90024","article-title":"Incidence of radiation-induced hypothyroidism following head and neck irradiation: a single-center analysis","volume":"27","author":"Jia-Mahasap B","year":"2022","unstructured":"Jia-Mahasap B, Assavanopakun K, Chitapanarux I, et al. Incidence of radiation-induced hypothyroidism following head and neck irradiation: a single-center analysis. Rep Pract Oncol Radiother 2022; 27: 90024.","journal-title":"Rep Pract Oncol Radiother"},{"key":"e_1_3_3_32_2","first-page":"89326","article-title":"Radiation-induced lung injury: what do we know in the era of modern radiotherapy?","volume":"27","author":"Konkol M","year":"2022","unstructured":"Konkol M, \u015aniata\u0142a P, Milecki P. Radiation-induced lung injury: what do we know in the era of modern radiotherapy? Rep Pract Oncol Radiother 2022; 27: 89326.","journal-title":"Rep Pract Oncol Radiother"},{"key":"e_1_3_3_33_2","first-page":"90768","article-title":"Thyroid function following radiation therapy in breast cancer patients: risk of radiation-induced hypothyroidism","volume":"27","author":"Farshchian N","year":"2022","unstructured":"Farshchian N, Amirifard N, Saiedian Azar MH, et al. Thyroid function following radiation therapy in breast cancer patients: risk of radiation-induced hypothyroidism. Rep Pract Oncol Radiother 2022; 27: 90768.","journal-title":"Rep Pract Oncol Radiother"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.5603\/RPOR.a2023.0010"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.5603\/RPOR.a2023.0043"},{"key":"e_1_3_3_36_2","first-page":"636","article-title":"Assessment of rectal toxicities after radiation therapy for localized prostate cancer: experience of the akanda cancer institute in Gabon","volume":"28","author":"Ndjembidouma M","year":"2023","unstructured":"Ndjembidouma M, James BC, G L, et al. Assessment of rectal toxicities after radiation therapy for localized prostate cancer: experience of the akanda cancer institute in Gabon. Rep Pract Oncol Radiother 2023; 28: 636\u2013645.","journal-title":"Rep Pract Oncol Radiother"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.5603\/GP.2020.0003"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-022-01492-7"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2020.07.020"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261422639","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552261422639","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261422639","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:32:24Z","timestamp":1777689144000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552261422639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":38,"alternative-id":["10.1177\/10781552261422639"],"URL":"https:\/\/doi.org\/10.1177\/10781552261422639","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"article-number":"10781552261422639"}}